

## An 11-Year Surveillance of HIV Type 1 Subtypes in Nagoya, Japan

Seiichiro Fujisaki, Shiro Ibe, Junko Hattori, Urara Shigemi, Saeko Fujisaki, Kayoko Shimizu, Kazuyo Nakamura, Yoshiyuki Yokomaku, Naoto Mamiya, Makoto Utsumi, Motohiro Hamaguchi, and Tsuguhiro Kaneda

### Abstract

To monitor active HIV-1 transmission in Nagoya, Japan, we have been determining the subtypes of HIV-1 infecting therapy-naïve individuals who have newly visited the Nagoya Medical Center since 1997. The subtypes were determined by phylogenetic analyses using the base sequences in three regions of the HIV-1 genes including *gag p17*, *pol protease (PR)* and *reverse transcriptase (RT)*, and *env C2V3*. Almost all HIV-1 subtypes from 1997 to 2007 and 93% of all HIV-1 isolates in 2007 were subtype B. HIV-1 subtypes A, C, D, and F have been detected sporadically since 1997, almost all in Africans and South Americans. The first detected circulating recombinant form (CRF) was CRF01\_AE (11-year average annual detection rate, 7.7%). Only two cases of CRF02\_AG were detected in 2006. A unique recombinant form (URF) was first detected in 1998 and the total number of URFs reached 25 by year 2007 (average annual detection rate, 4.7%). Eleven of these 25 were detected from 2000 to 2005 and had subtypes AE/B/AE as determined by base sequencing of the *gag p17*, *pol PR* and *RT*, and *env C2V3* genes (average annual detection rate, 3.7%). Unique subtype B has been detected in six cases since 2006. All 17 of these patients were Japanese. Other recombinant HIV-1s have been detected intermittently in eight cases since 1998. During the 11-year surveillance, most HIV-1s in Nagoya, Japan were of subtype B. We expect that subtype B HIV-1 will continue to predominate for the next several years. Active recombination between subtype B and CRF01\_AE HIV-1 and its transmission were also shown.

### Introduction

THE TOTAL NUMBER OF HIV-1-INFECTED INDIVIDUALS and the prevalence of HIV-1 in Japan were 13,842 and 0.01%, respectively, at the end of 2007, which is far less than the number and prevalence in other Asian countries.<sup>1-6</sup> However, the number of newly infected patients per year was still increasing in Japan in 2007, when it reached 1448. One-hundred and twenty-five (8.6%) new patients were identified in Aichi prefecture in the same year. The total number of HIV-1-infected individuals and the prevalence of HIV in Aichi prefecture in 2007 were 725 and 0.01%, respectively. The number of newly infected individuals is expected to increase further. Therefore, the rapid increase in the number of HIV-1-infected individuals and changes in HIV-1 subtype populations are matters of great concern.

The most prevalent HIV-1 subtype in the world is subtype C (50%) followed by A (12%), B (10%), G (6%), and D (3%).<sup>7,8</sup> In addition, there are circulating recombinant forms (CRFs), such as CRF01\_AE, CRF02\_AG, and other recombi-

nant viruses. The prevalent HIV-1 subtypes in China, Japan's largest neighbor, are circulating B/C recombinant forms, CRF07\_BC, and CRF08\_BC, accounting for 50% of the HIV-1-infected population, and subtype B HIV-1 accounting for 32%.<sup>9</sup> In contrast, the most prevalent HIV-1 strains in Japan are subtype B (83.1%) and CRF01\_AE (12.4%) according to the nationwide surveillance.<sup>10</sup> It is clear that the distribution of HIV-1 strains is very different in Japan than in the rest of the world. However, as subtypes were determined from the base sequence of the *pol protease (PR)* and *reverse transcriptase (RT)* genes, we could not identify recombinant HIV-1 subtypes.

To study the trend of HIV-1 subtypes and the emergence of recombinant HIV-1 subtypes in Nagoya, Japan, we selected the *gag p17*, *env C2V3*, and *PR to RT* gene. We determined the base sequences of these genes from 2003; the subtypes of HIV-1 samples from 1997 to 2002 were retrospectively determined by the same method. Finally, this study aimed to clarify the genetic changes in HIV-1 subtypes by monitoring the sequences of HIV-1 subtypes that infected therapy-naïve patients between 1997 and 2007.

Clinical Research Center, National Hospital Organization Nagoya Medical Center (Tokai Area Central Hospital for AIDS Treatment and Research), Nagoya, Aichi 460-0001, Japan.

TABLE 1. SUBTYPE DISTRIBUTION OF THERAPY-NAIVE HIV-1-INFECTED PATIENTS

	Total	A	B	C	D	F	CRF01_AE	CRF02_AG	Other recombinants
Number of patients	534	10 (1.9%)	440 (82.4%)	11 (2.1%)	1 (0.2%)	4 (0.7%)	41 (7.7%)	2 (0.4%)	25 (4.7%)
Age									
Average	37	31	37	38	32	24	40	37	35
Range	17-73	20-40	17-73	22-66	—	21-28	20-69	33-41	20-53
CD4 <sup>+</sup> T cells (cells/ $\mu$ l)									
Average	280	305	278	291	418	468	246	289	264
Range	0-1508	60-1003	0-1508	7-545	—	278-909	2-1200	210-367	1-716
Viral load (copies/ml)									
Average	$3.1 \times 10^5$	$1.8 \times 10^5$	$3.3 \times 10^5$	$8.6 \times 10^4$	$2.5 \times 10^4$	$2.2 \times 10^4$	$2.7 \times 10^5$	$5.1 \times 10^4$	$2.9 \times 10^5$
Range	$1.0 \times 10^2$ - $1.3 \times 10^7$	$4.4 \times 10^2$ - $1.1 \times 10^6$	$1.0 \times 10^2$ - $1.3 \times 10^7$	$6.1 \times 10^2$ - $4.3 \times 10^5$	—	$2.1 \times 10^3$ - $4.5 \times 10^4$	$7.8 \times 10^2$ - $2.8 \times 10^6$	$4.4 \times 10^4$ - $5.7 \times 10^4$	$2.8 \times 10^2$ - $2.0 \times 10^6$
Clinical phase <sup>a</sup>									
AC	370	6	302	9	1	4	25	2	21
ARC	37	2	32	0	0	0	3	0	0
AIDS	127	2	106	2	0	0	13	0	4

<sup>a</sup>AC, asymptomatic carrier; ARC, AIDS-related complex.

## Materials and Methods

### Patients

We enrolled 534 therapy-naive HIV-1-infected patients who initially attended our HIV-1 clinic at Nagoya Medical Center in Nagoya, Japan, between June 1997 and December 2007 and gave their written, informed consent to participate in our study. Our research protocol was approved by the ethical committee in our hospital. The samples of this study were the same ones used for drug resistance testing, which was conducted in almost all therapy-naive individuals at their initial visit. The data, including age, nationality, sexual orientation, number of CD4-positive T cells, and viral load, were obtained from medical records.

### Patient coverage by Nagoya Medical Center

Nagoya Medical Center is located in Nagoya City, the capital of Aichi prefecture, and is the central hospital for AIDS treatment and research in the Tokai area (which includes the Aichi, Mie, Gifu, and Shizuoka prefectures).

### Amplification of HIV-1 DNA fragments and determinations of DNA sequences

HIV-1 RNA was extracted from plasma samples using a QIAamp viral RNA Mini Kit (QIAGEN, Tokyo, Japan). The DNA fragments were amplified by reverse transcription-nested polymerase chain reaction (RT-nested PCR) using the Superscript one-step RT-PCR system (Invitrogen, Tokyo, Japan) and LA Taq polymerase (Takara, Shiga, Japan). The primers used for DNA amplification were as follows. The *gag* fragment containing the region between *gag p17* and *p24* (codons 1-147 encoding *gag-pol polyprotein*) was amplified by RT-PCR with the primer set of 172A (5'-ATC TCT AGC AGT GGC GCC CGA ACA G-3') and 173B (5'-CTG ATA ATG CTG AAA ACA TGG GTA T-3').<sup>11</sup> 174A (5'-CTC TCG ACG CAG GAC TCG GCT TGC T-3') and 175B (5'-CCC ATG CAT TCA AAG TTC TAG GTG A-3') were used for nested PCR. The *pol* fragments containing the regions encoding *gag-pol polyprotein* (codons 425-500), *PR* (codons 1-99), and *RT* (codons 1-349) were amplified by RT-PCR with primers of K1 (5'-AAG GGC TGT TGG AAA TGT GG-3') and U13 (5'-CCC ACT CAG GAA TCC AGG T-3').<sup>12</sup> K4 (5'-GAA AGG AAG GAC ACC AAA TGA-3') and U12 (5'-CTC ATT CTT GCA TAT TTT CCT GTT-3') were used for nested PCR. The *env* fragment containing the region encoding *env C2V3* (codons 249-375) was amplified by RT-PCR with primers of 106A (5'-CAT ACA TTA TTG TGC CCC GGC TGG-3') and 17B (5'-AGA AAA ATT CCC CTC TAC AAT TAA-3').<sup>11</sup> 14A (5'-AAT GTC AGC TCA GTA CAA TGC ACA C-3') and 10B (5'-ATT TCT GGG TCC CCT GAG G-3') were used for nested PCR. These are in-house primers capable of amplifying the target genes of different HIV-1 subtypes. The *gag*, *pol*, and *env* gene fragments were not amplified in RT-nested PCR using the above-mentioned primers in four, five, and nine cases, respectively. In such cases, different primer sets were used (not shown). Thus, amplified cDNAs were successfully obtained in all cases.

An HIV-1 DNA control, in which reverse transcriptase was omitted in the RT-PCR, was run in parallel with RT-PCR to control for the absence of genomic DNA. The PCR products were purified using the QIAGEN Gel Extraction Kit

(QIAGEN). A labeling reaction for DNA sequencing was performed using the same primers used for the PCR reactions as well as the BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems, Tokyo, Japan), and then labeled DNA fragments were purified on a AutoSeq G-50 column (GE Healthcare, Tokyo, Japan). The samples were analyzed by direct sequencing and electropherograms were obtained using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). DNA sequences were analyzed using Sequencing Analysis V3.7 (Applied Biosystems) and SeqScape V2.5 (Applied Biosystems).

**Subtype determination**

Sequences were analyzed and grouped into subtypes by phylogenetic tree construction. Phylogenetic analysis using nucleotide sequences of *gag* fragments from 534 therapy-naive patients was performed using the 62 reference HIV-1 sequences derived from the Los Alamos National Laboratory database.<sup>13</sup> The 62 sequences represent all subtypes of the major groups and 18 CRFs. Independent analysis was done using both *pol* fragments and *env* fragments. Sequences

were aligned using CLUSTAL W software in MEGA software version 3.1. Evolutionary distances were calculated using the same software. Phylogenetic trees were constructed by the neighbor-joining method based on distances calculated with Kimura's two-parameter algorithm. The reliabilities of the branching patterns were tested by bootstrap analysis with 1000 replicates.

**Results**

*HIV-1 subtypes in the last 11 years in Nagoya*

Subtype B was the most prevalent subtype, identified in 440 out of 534 patients (82.4%, Table 1 and Fig. 1). The largest number, 388, was found in Japanese and the next largest, 45, in South Americans (Table 2). Of the total number, 319 were identified in Japanese men who have sex with men (MSM) and 14 in South American MSM. Of note, the 72.5% infected with subtype B HIV-1 were Japanese MSM. Infection with subtypes A, C, D, and F was detected in 10 individuals (seven Africans, one East European, and two Japanese), 11 individuals (two Africans, two South Americans, two Southwest




FIG. 1. Subtypes of HIV-1 found in therapy-naive infected patients in Nagoya Medical Center from 1997 to 2007 (upper panel). The numbers of patients (bars) and their proportions (% in parentheses) are shown. The numbers of patients and their nationalities (indicated by a color: Japan, red; East Asia, green; Southwest Asia, blue; South America, orange; North America, pink; Eastern Europe, black; Africa, uncolored) are given in the lower panel.

TABLE 2. NATIONALITIES AND SEXUAL ORIENTATIONS OF THERAPY-NAIVE HIV-1-INFECTED PATIENTS BY SUBTYPES<sup>a</sup>

	Total	A	B	C	D	F	CRF01_AE	CRF02_AG	Other recombinants
Nationalities									
Japan	439 (420, 340)	2 (0, 0)	388 (381, 319)	5 (1, 1)	0	0	23 (20, 2)	2 (0, 0)	19 (18, 18)
East Asia	6 (4, 4)	0	4 (4, 4)	0	0	0	1 (0, 0)	0	1 (0, 0)
Southwest Asia	18 (9, 0)	0	1 (0, 0)	2 (1, 0)	0	0	15 (8, 0)	0	0
East Europe	2 (0, 0)	1 (0, 0)	0	0	0	0	0	0	1 (0, 0)
North America	2 (2, 2)	0	2 (2, 2)	0	0	0	0	0	0
South America	55 (36, 15)	0	45 (31, 14)	2 (1, 0)	0	4 (1, 0)	2 (1, 0)	0	2 (2, 1)
Africa	12 (9, 0)	7 (5, 0)	0	2 (1, 0)	1 (1, 0)	0	0	0	2 (2, 0)

<sup>a</sup>The left and right numbers in parentheses are the numbers of males and MSMs, respectively.

Asians, and five Japanese), one African, and four South Americans, respectively. In foreigners, this distribution of HIV-1 subtypes represents the distribution of subtypes commonly found in the immigrants' region of origin.<sup>14-20</sup> However, subtypes A and C were detected mostly in Japanese females who seemed to have acquired the infection from foreign partners in Japan.

As for circulating recombinant forms (CRFs), CRF01\_AE was detected in 41 individuals (7.7%), including 23 Japanese (18 non-MSM, two MSM, and three females) and 18 foreigners (nine non-MSM and nine females). Considering that only four individuals (two Japanese males, one Japanese female, and

one South Asian female) were intravenous drug users, CRF01\_AE has mainly spread through heterosexual contact in Nagoya. CRF02\_AG was detected in two individuals (0.4%) in 2006 (Fig. 2).

Among other recombinant forms, the most frequent was AE/B/AE, found in 11 Japanese MSM. A unique subtype B HIV-1 strain that possessed subtype D fragments in the *gag* and *env* regions was also detected in six Japanese MSM. As for other recombinants, A/D/A, D/D/A, and AE/B/B were each identified in two individuals and A/B/A and B/B/F were each identified in one. Thirteen intravenous drug users (2.4%) were included: two male Japanese with subtype B, one female




FIG. 2. Recombinant HIV-1s detected in therapy-naive patients in Nagoya Medical Center (upper panel). The bars indicate the number of recombinant HIV-1s detected from 1997 to 2007. The number of patients and their nationalities (indicated by J, Japan; EA, East Asia; SAs, Southwest Asia; SAm, South America; A, Africa; NA, North America; EE, Eastern Europe) are shown in the lower panel.

Japanese with CRF01\_AE, four MSM with a unique subtype B, two male South Americans with subtype B, and two male and one female Southwest Asians with CRF01\_AE.

*The change of HIV-1 detection rates*

The rate of subtype B detection, the most frequently detected HIV-1 subtype in the Nagoya Medical Center, increased to 93% in 2007 (Fig. 1). During this period, the absolute number of individuals with subtype B HIV-1 also increased. On the other hand, the number of individuals infected with non-B HIV-1 strains fluctuated between 7 and 15 after the year 2000. Major subtypes A, C, D, and F were sporadically detected (only two or three cases per year since 2004). The most frequently detected circulating recombinant HIV-1 was CRF01\_AE, which was detected every year from 1997 to the present, except for 1999 (Fig. 2). About half of these

infections were in Japanese and the other half were in Southwest Asians. No increase in the number of infections by this virus has been observed. The increase in the number of HIV-1-infected cases, especially of subtype B, during the past 11 years reflected the scaling up of clinical services as well as the increase in HIV-1 transmission.

*Active recombination between subtype B and CRF01\_AE HIV-1*

The A/D/A recombinant was first detected in 1998 (Fig. 2), and unique recombinant forms (URFs) have been detected in all years except 1999. The AE/B/AE recombinant, the most frequently detected URF, had been detected between 2000 and 2005, and the accumulated number of cases with this virus was 11. A unique subtype B HIV-1 was detected in five patients and one patient in 2006 and 2007, respectively.




FIG. 3. Phylogenetic tree analyses of 11 recombinant AE/B/AE HIV-1s. Trees were constructed using nucleotide base sequences of *gag p17* (A), *pol PR to RT* (B), and *env C2V3* (C) gene regions. The base sequences of the *gag p17* and *env C2V3* genes of 41 CRF01\_AE HIV-1s and those of the *pol PR to RT* gene of 440 subtype B HIV-1s in this study (Table 1) as well as 39 reference sequences obtained from the Los Alamos database were used for these analyses. Clustered AE/B/AE recombinant HIV-1s indicated by red, blue, and green circles are framed. Red circles represent HIV-1s that form a cluster in all trees. Green circles represent HIV-1s that form a cluster only in trees with *gag* and *env* genes. Blue circles represent HIV-1s that form a cluster only in trees with *gag* and *pol* genes. Candidate HIV-1s with subtype B or CRF01\_AE accounting for AE/B/AE recombinant formation are depicted by open triangles (B) and open circles (A and C), respectively.

The detection of one A/D/A, one D/D/A, two AE/B/B, one A/B/A, and one B/B/F was sporadic from 2001 to 2004. The A/D/A, D/D/A, AE/B/B, A/B/A, B/B/F, and unique B recombinants may have been brought from foreign countries because no candidate sequences indicating the origin of A, D, F, and CRF01\_AE have been found. Of course, patients infected with these recombinant viruses may have been partners in a sexual network with less access to medical care. Nine viruses of the AE/B/AE recombinant form (represented with red circles in Fig. 3) were clustered in three separate phylogenetic analyses of the *gag p17*, *env C2V3*, and *pol PR* to *RT* genes, indicating that they were closely related. In addition, CRF01\_AE of patient 115 was positioned in the same cluster of *gag* and *env* sequences mentioned above, and subtype B of patient 135 in the same cluster of *pol* sequence, suggesting this AE/B/AE recombinant form may be originated from these two viruses.

## Discussion

In this study, the emergence and transmission of recombinant HIV-1s were analyzed in detail by determining base sequences of major segments of three genes: *gag p17*, *pol PR* to *RT*, and *env C2V3*. The subtypes of HIV-1 strains prevalent in the Nagoya Medical Center for the past 11 years were B (82.4%), CRF01\_AE (7.7%), C (2.1%), A (1.9%), F (0.7%), CRF02\_AG (0.4%), D (0.2%), and other recombinant forms (4.7%). This result was similar to the result of a nationwide study (using only the *pol PR* to *RT* gene region to determine subtypes<sup>10</sup>), which found that only 5% of the total cases were due to recombinant forms. Worldwide, subtype C is the most prevalent HIV-1 subtype (50% of all cases).<sup>8,9</sup> This means the situation in Nagoya, Japan is quite different from that in other parts of the world, especially from that in Africa.

The recombinant HIV-1s, in addition to CRF01\_AE and CRF02\_AG, include 11 AE/B/AE, six unique subtype B recombinants possessing short D fragments in *gag* and *env* genes, two A/D/A, two D/D/A, two AE/B/B, one A/B/A, and one B/B/F. Among these seven, all except AE/B/AE appear to be immigrant types. Only the AE/B/AE type seems to be a newly emerged recombinant in our area. As subtype B was the predominant HIV-1 subtype and CRF01\_AE was the second-most prevalent HIV-1 recombinant in Nagoya, we have speculated that a novel recombinant HIV-1 between subtype B and CRF01\_AE will emerge in this area. The methodology for subtype determination using the base sequences of *gag p17*, *pol PR* to *RT*, and *env C2V3* genes is useful at the moment; however, to clarify the gene structure of these recombinant viruses, analysis of the full sequence and then computational analyses are required. Use of this approach revealed that the gene structure of AE/B/AE type recombinants found in this study is novel and differs from that of CRF15\_01B, CRF33\_01B, and CRF34\_01B (i.e., CRFs resulting from recombination between subtype B and CRF01\_AE HIV-1 found in Malaysia and Thailand).<sup>21–23</sup> The finding of two viruses with genes for both subtype B and CRF01\_AE, which are the candidate origins of this AE/B/AE recombinant, supported our hypothesis of emerging recombinants. The number of HIV-1-infected individuals as well as the frequency of drug-resistant HIV-1 in therapy-naïve individuals have increased, strongly implying that this increasing tendency will continue in Nagoya, Japan.<sup>24,25</sup> We will pursue this kind

of surveillance to obtain information needed for suppressing the spread of HIV-1 infection.

## Sequence Data

The base sequences of HIV-1 subtypes are registered in the DNA databank of Japan (DDBJ) as AB442228–AB443428 and AB356098–AB356499.

## Acknowledgments

This study was supported by a grant for research on HIV/AIDS from the Ministry of Health, Labour, and Welfare of Japan (No. H19-AIDS-028). Junko Hattori and Saeko Fujisaki are research residents of the Japanese Foundation for AIDS Prevention.

## Disclosure Statement

No competing financial interests exist.

## References

1. Japanese Foundation of AIDS Prevention: <http://www.jfap.or.jp/english/index.htm>.
2. Wu Z, Sun X, Sullivan SG, and Detels R: HIV testing in China. *Science* 2006;312:1475–1476.
3. Wu Z, Sullivan SG, Wang Y, *et al.*: Evolution of China's response to HIV/AIDS. *Lancet* 2007;369:679–690.
4. Steinbrook R: HIV in India—a complex epidemic. *N Engl J Med* 2007;356:1089–1093.
5. Wirachsilp P, Kantakamalakul W, Foongladda S, *et al.*: Surveillance of subtype and genetic variation of the circulating strains of HIV-1 in Thailand. *Southeast Asian J Trop Med Public Health* 2007;38:814–827.
6. Chang SY, Sheng WH, Lee CN, *et al.*: Molecular epidemiology of HIV type 1 subtypes in Taiwan: Outbreak of HIV type 1 CRF07\_BC infection in intravenous drug users. *AIDS Res Hum Retroviruses* 2006;22:1055–1066.
7. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* 2006;20:W13–23.
8. McCutchan FE: Global epidemiology of HIV. *J Med Virol* 2006;78:S7–S12.
9. Zhong P, Pan Q, Ning Z, *et al.*: Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. *AIDS Res Hum Retroviruses* 2007;23:847–856.
10. Gatanaga H, Ibe S, Matsuda M, *et al.*: Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. *Antiviral Res* 2007;75:75–82.
11. Kato K, Shiino T, Kusagawa S, *et al.*: Genetic similarity of HIV type 1 subtype E in a recent outbreak among injecting drug users in northern Vietnam to strains in Guangxi Province of southern China. *AIDS Res Hum Retroviruses* 1999;15:1157–1168.
12. Ibe S, Shibata N, Utsumi M, and Kaneda T: Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6<sup>gag</sup> and p6<sup>pol</sup> genes under highly active antiretroviral therapy. *Microbiol Immunol* 2003; 47:71–79.
13. Los Alamos HIV Sequence Database: <http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html>.
14. Katzenstein D: Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. *J Infect Dis* 2006;194:S45–50.

15. Herbeck JT, Lyagoba F, Moore SW, *et al.*: Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. *AIDS Res Hum Retroviruses* 2007;23:755–760.
16. Baker CA, Bousheri S, Ssewanyana I, *et al.*: HIV subtypes distribution and implication for antiretroviral treatment in a Ugandan population. *J Int Assoc Phys AIDS Care* 2007; 6:260–263.
17. Trask SA, Derdeyn CA, Fideli U, *et al.*: Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. *J Virol* 2002;76:397–405.
18. Bello G, Guimarães ML, and Morgado MG: Evolutionary history of HIV-1 subtype B and F infections in Brazil. *AIDS* 2006;20:763–768.
19. Eyer-Silva WA, Couto-Fernandez JC, and Morgado MG: Molecular epidemiology of HIV type 1 in inner Rio De Janeiro State, Brazil. *AIDS Res Hum Retroviruses* 2007;23:303–308.
20. Varella RB, Ferreira SB, de Castro MB, Zalis MG, and Tavares MD: Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naïve patients in different stages of infection in Rio de Janeiro, Brazil. *J Med Virol* 2007;79:1033–1039.
21. Tovanabutra S, Watanaveeradej V, Viputtikul K, *et al.*: A new circulating recombinant form, CRF15\_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand. *AIDS Res Hum Retroviruses* 2003;19:561–567.
22. Tee KK, Li XJ, Nohtomi K, Ng KP, Kamarulzaman A, and Takebe Y: Identification of a novel circulating recombinant form (CRF33\_01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. *J Acquir Immune Defic Syndr* 2006;43:523–529.
23. Tovanabutra S, Kijak GH, Beyrer C, *et al.*: Identification of CRF34\_01B, a second circulating recombinant form unrelated to and more complex than CRF15\_01B, among injecting drug users in northern Thailand. *AIDS Res Hum Retroviruses* 2007;23:829–833.
24. Ibe S, Hotta N, Takeo U, *et al.*: Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naïve patients and usefulness of genotype testing. *Microbiol Immunol* 2003;47:499–505.
25. Ibe S, Hattori J, Fujisaki S, *et al.*: Trend of drug-resistant HIV type 1 emergence among therapy-naïve patients in Nagoya, Japan: An 8-year surveillance from 1999 to 2006. *AIDS Res Hum Retroviruses* 2008;24:7–14.

Address reprint requests to:

*Tsuguhiro Kaneda*

*Clinical Research Center*

*National Hospital Organization Nagoya Medical Center*

*Sannomaru 4-1-1*

*Naka-ku, Nagoya, Aichi 460-0001, Japan*

*E-mail: kanedat@nnh.hosp.go.jp*



